The biotech industry stands at a pivotal moment as the potential end of Chevron deference – a legal doctrine shaping regulatory interpretations – comes to into focus. This legal shift could redefine how agencies like the FDA navigate regulations, opening door for innovation while introducing new challenges.
In this BioSpace opinion piece, The End of Chevron Deference Could Open a New Era of Biotech, Project Farma President Anshul Mangal discusses how these changes could impact compliance, legal strategies, and the pace of biotech advancements.
Read “Opinion: The End of Chevron Deference Could Open a New Era of Biotech”, for Anshul’s thought-provoking analysisBig published in BioSpace.
